Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema

Shahid Beheshti University of Medical Sciences1 site in 1 country150 target enrollmentNovember 2005

ConditionsDiabetic Macular Edema

Drugsbevacizumab triamcinolone acetonide

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Diabetic Macular Edema
Sponsor: Shahid Beheshti University of Medical Sciences
Enrollment: 150
Locations: 1
Primary Endpoint: visual acuity
Last Updated: 19 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)

Detailed Description

we entered 150 eyes into the study that recruitment of cases finished recently.Eligible eyes randomly assign to one of the study arms including intravitreal bevacizumzb, intravitreal bevacizumzb/triamcinolone and macular photocoagulation groups. Every patient needs at least 1 year followup. During this time BCVA, OCT, FA will be done for each patient and inaccording to interpretation of datas and fundus exam repeatation of injection will be done.

Registry

clinicaltrials.gov

Start Date

November 2005

End Date

February 2007

Last Updated

19 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shahid Beheshti University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•case with clear media IOP below 23 mm/Hg female after menopause at least for 12 months or had 2 contraceptive roots visual acuity between 20/50 to 20/320

Exclusion Criteria

•no PRP or N.d YAG laser in past 6 months no intraocular surgery in past 12 months
•CVA in past 12 months blood sugar above 250
•active infection in extraocular adnexa